MetaCap

Boundless Bio (BOLD) vs Tenax Therapeutics (TENX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Tenax Therapeutics (TENX) over the past year, gaining 105.3% versus a loss of 84.7%. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $54.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%TENX-84.66%
+178%+40%-97%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%TENX-70.52%
+334%+111%-113%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus TENX key metrics
MetricBOLDTENX
Share price$2.32$1.25
Market cap$54.78M$56.92M
1-day change-2.52%-10.07%
YTD return+93.33%-89.75%
1-year return+105.31%-84.66%
5-year return—-99.94%
EPS (TTM)$-2.46$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-58.20M$-52.60M
52-week high$3.16$19.40
52-week low$0.961$1.24
Distance from 52-week high-26.68%-93.56%
Analyst consensusnonenone
Avg. price target upside+72.41%+904.80%
Average volume131.34K3.15M
Shares outstanding23.61M45.54M
Employees2814
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed TENX by 190.0 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

BOLD vs TENX FAQ

Which is bigger, Boundless Bio or Tenax Therapeutics?

Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $54.78M for Boundless Bio (BOLD).

Which stock has performed better over the past year, BOLD or TENX?

BOLD returned +105.31% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and Tenax Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons